QurCan Therapeutics has developed the next-generation polymer-lipid nanoparticles that facilitate safe and non-immunogenic delivery of biologics, including RNA, peptides, and antibodies, to selected cells and tissues, including CNS and spleen. QurCan has two immunomodulatory cancer therapeutics in its pipeline and a strong IP portfolio. At BIO 2023, the company is seeking global partners to develop new RNA/DNA therapies using its proprietary, drug-delivery platform to treat cancer and neurodegenerative diseases.

QurCan Therapeutics logo



Event details

Date: June 5 - 8, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


33 in total